KYMR
USDKymera Therapeutics Inc. Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$55.800
Максимум
$61.580
Минимум
$55.660
Объем
0.77M
Фундаментальные показатели компании
Рыночная капитализация
4.3B
Отрасль
Биотехнология
Страна
United States
Статистические данные торговли
Средний объем
0.75M
Биржа
NGM
Валюта
USD
52-недельный диапазон
Связанные новости
Guggenheim Assumes Kymera Therapeutics at Buy, Announces Price Target of $90
Guggenheim analyst Brad Canino assumes Kymera Therapeutics with a Buy rating and announces Price Target of $90.
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $75
BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics with a Buy and raises the price target from $59 to $75.
Mizuho Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $81
Mizuho analyst Joseph Catanzaro initiates coverage on Kymera Therapeutics with a Outperform rating and announces Price Target of $81.
Связанные акции
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.